Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10362/187787
Título: | Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes |
Autor: | Chen, Huanwen Colasurdo, Marco Matsukawa, Hidetoshi Cunningham, Conor Maier, Ilko Al Kasab, Sami Jabbour, Pascal Kim, Joon Tae Wolfe, Stacey Quintero Rai, Ansaar Starke, Robert M. Psychogios, Marios Nikos Samaniego, Edgar A. Goyal, Nitin Yoshimura, Shinichi Cuellar, Hugo Grossberg, Jonathan A. Alawieh, Ali Alaraj, Ali Ezzeldin, Mohamad Romano, Daniele G. Tanweer, Omar Mascitelli, Justin Fragata, Isabel Polifka, Adam Siddiqui, Fazeel Osbun, Joshua Crosa, Roberto Matouk, Charles Park, Min S. Levitt, Michael R. Brinjikji, Waleed Moss, Mark Dumont, Travis Daglioglu, Ergun Williamson, Richard Navia, Pedro Leacy, Reade De Chowdhry, Shakeel Altschul, David J. Spiotta, Alejandro M. Kan, Peter |
Palavras-chave: | ASPECT Basilar computed tomography hemorrhage imaging magnetic resonance perfusion stroke thrombectomy time window Clinical Neurology Cardiology and Cardiovascular Medicine |
Data: | Ago-2025 |
Resumo: | Introduction: Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods: This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results: 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts (p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p > 0.05). Conclusions: Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice. |
Descrição: | Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Chen: None. Dr Colasurdo: None. Dr Matsukawa received a lecture fee from Daiichi-Sankyo and Stryker and consulting services fee from B. Braun. Dr Al Kasab: grant from Stryker for RESCUE-ICAS registry. Dr Cunningham: None. Dr Maier: Speakers honoraria from Pfizer and Bristol-Myers Squibb. Dr Jabbour: None. Dr Kim: None. Dr Wolfe: None. Dr Rai: None. Dr Starke: RMS research is supported by the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, Department of Health Biomedical Research Grant (21K02AWD-007000), and by National Institute of Health (R01NS111119-01A1) and (UL1TR002736, KL2TR002737) through the Miami Clinical and Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. RMS has an unrestricted research grant from Medtronic and Balt and has consulting and teaching agreements with Penumbra, Abbott, Medtronic, Balt, InNeuroCo, Cerenovus, Naglreiter, Tonbridge, Von Medical, and Optimize Vascular. Dr Psychogios: Grants from the Swiss National Science Foundation (SNF) for the DISTAL trial (33IC30_198783) and TECNO trial (32003B_204977), Grant from Bangerter-Rhyner Stiftung for the DISTAL trial. Unrestricted Grants for the DISTAL trial from Stryker Neurovascular Inc., Phenox GmbH, Penumbra Inc. and Rapid Medical Inc., Sponsor-PI SPINNERS trial (Funded by a Siemens Healthineers AG Grant), Research agreement with Siemens Healthineers AG, Local PI for the ASSIST, EXCELLENT, TENSION, COATING, SURF, and ESCAPE-NEXT trials. Speaker fees: Stryker Neurovascular Inc., Medtronic Inc., Penumbra Inc., Acandis GmbH, Phenox GmbH, Siemens Healthineers AG. Dr Samaniego: None. Dr Arthur: Consultant for Arsenal, Balt, Johnson and Johnson, Medtronic, Microvention, Penumbra, Perfuze, Scientia, Siemens, Stryker. Research support from Balt, Medtronic, Microvention, Penumbra, and Siemens. Shareholder Azimuth, Bendit, Cerebrotech, Endostream, Magneto, Mentice, Neurogami, Neuros, Perfuze, Revbio, Scientia, Serenity, Synchron, Tulavi, Vastrax, VizAI. Dr Yoshimura received a lecture fee from Stryker, Medtronic, Johnson & Johnson, Kaneka Medics. Dr Cuellar: Dr Hugo Cuellar: Consultant for Medtronic, Penumbra and Microvention. Dr Grossberg: None. Dr Alawieh: None. Dr Tanweer: None. Dr Mascitelli: None. Dr Fragata: None. Dr Polifka: None. Dr Osbun: None. Dr Crosa: None. Dr Matouk: Consultant for Stryker, Medtronic, Microvention, Penumbra, and Silk Road Medical. Speaker for Penumbra and Silk Road Medical. Contact PI for NIH Grant R21NS128641. Dr Park: Consultant for Medtronic. Dr Levitt: Unrestricted educational grants from Medtronic and Stryker; consulting agreement with Medtronic, Aeaean Advisers and Metis Innovative; equity interest in Proprio, Stroke Diagnostics, Apertur, Stereotaxis, Fluid Biomed, and Hyperion Surgical; editorial board of Journal of NeuroInterventional Surgery, data safety monitoring board of Arsenal Medical. Dr Brinjikji: None. Dr Moss: None. Dr Dumont: None. Dr Williamson: Consultant for Medtronic, Stryker, and Synaptive Medical. Dr Navia: Consultant for Penumbra, Medtronic, Stryker, Cerenovus, and Balt. Dr Leacy: Research grants from Siemens Healthineers and Kaneka medical. Consultant for Cerenovus, Stryker Neurovascular and Scientia Vascular. Minor equity interest Vastrax, Borvo medical, Synchron, Endostream, Von Vascular. Dr Chowdhry: Consultant and proctor for Medtronic and Microvention. Dr Ezzeldin: Speaker for Viz.ai and has stocks in Galaxy Therapeutics. Dr Spiotta: Research support from Penumbra, Stryker, Medtronic, and RapidAI. Consultant for Penumbra, Stryker, Terumo, and RapidAI. Dr Kan: Grants from the NIH (1U18EB029353-01) and unrestricted educational grants from Medtronic and Siemens. Consultant for Imperative Care and Stryker Neurovascular. Stock ownership in Vena Medical. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The STAR registry receives research support from Penumbra, Microvention, Medtronic, Stryker, RapidAI, Brain Aneurysm Foundation. Publisher Copyright: © European Stroke Organisation 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
Peer review: | yes |
URI: | http://hdl.handle.net/10362/187787 |
DOI: | https://doi.org/10.1177/23969873251364973 |
ISSN: | 2396-9873 |
Aparece nas colecções: | Home collection (NMS) |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
chen-et-al-2025-conventional-versus-advanced-imaging-selection-for-endovascular-treatment-of-basilar-artery-occlusion.pdf | 1,04 MB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.